JTL
CRNX icon

Jupiter Topco LLC’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jupiter Topco LLC’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171M Buy
+4,557,689
New +$169M 0.07% 236

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Jupiter Topco LLC's CRNX Position: Q2 2026 in Review

Jupiter Topco LLC opened a new position in Crinetics Pharmaceuticals (CRNX) in Q2 2026: 4,557,689 shares worth $171M. The stake represents 0.07% of the portfolio and ranks #236 among its holdings.

250 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Jupiter Topco LLC held 4,557,689 shares of Crinetics Pharmaceuticals worth $171M as of Q2 2026.
  • Crinetics Pharmaceuticals was a new Jupiter Topco LLC position in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.07% of Jupiter Topco LLC's portfolio in Q2 2026, its #236 holding.
  • 250 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Jupiter Topco LLC's 13F filing for Q2 2026, filed 14 Aug 2026.